<DOC>
	<DOCNO>NCT01739452</DOCNO>
	<brief_summary>Reviewing Spanish record myelodysplastic syndrome ( RESMD ) data base group patient MDS . The information collect retrospectively diagnosis MDS , date December 31 , 2011 .</brief_summary>
	<brief_title>Spanish Registry Erythropoietic Stimulating Agents Study</brief_title>
	<detailed_description>Review RESMD data base group patient MDS diagnosis low risk myelodysplastic syndrome ( MDS ) occurrence anemia begin treatment erythropoiesis stimulate agent ( ESAs ) / support transfusional December 31 , 2011 . In case , data obtain prior date start study ensure retrospective nature , thus reflect routine use erythropoietic agent clinical non-interference doctor 's clinical practice .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>The patient give consent collection data RESMD . Age ≥ 18 year . Patient must diagnose MDS accord WHO classification FAB lowrisk ( IPSS low intermediate1 ) anemia ( Hb ≤ 11 g / dL ) . The patient study time diagnosis discard possibility MDS anemia due deficiency factor ( iron , vitamin B12 folic acid ) . Initiation treatment ESAs support transfusional spanish hematology service December 31 , 2011 . Pretreatment SMD hypomethylating agent , lenalidomide , chemotherapy , .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Low-risk MDS</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>retrospective</keyword>
</DOC>